Jefferies Group Increases Bruker Corp. Price Target to $27.00 (BRKR)
Jefferies Group lifted their target price on shares of Bruker Corp. (NASDAQ:BRKR) from $24.00 to $27.00 in a research note issued on Wednesday, ARN reports. Jefferies Group’s price objective would suggest a potential upside of 23.51% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at UBS AG raised their price target on shares of Bruker Corp. from $23.00 to $25.00 in a research note on Wednesday. Separately, analysts at ISI Group raised their price target on shares of Bruker Corp. from $23.50 to $24.50 in a research note on Wednesday. Finally, analysts at Zacks downgraded shares of Bruker Corp. from a “neutral” rating to an “underperform” rating in a research note on Thursday, January 2nd. They now have a $18.80 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $23.53.
Bruker Corp. (NASDAQ:BRKR) traded up 2.70% on Wednesday, hitting $22.45. 3,063,317 shares of the company’s stock traded hands. Bruker Corp. has a one year low of $15.41 and a one year high of $23.71. The stock has a 50-day moving average of $20.62 and a 200-day moving average of $20.01. The company has a market cap of $3.753 billion and a P/E ratio of 64.29.
Bruker Corp. (NASDAQ:BRKR) last announced its earnings results on Tuesday, February 18th. The company reported $0.31 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.22 by $0.09. The company had revenue of $552.10 million for the quarter, compared to the consensus estimate of $452.14 million. On average, analysts predict that Bruker Corp. will post $0.88 earnings per share for the current fiscal year.
Bruker Corporation (NASDAQ:BRKR) is a global manufacturer of scientific instruments that address the rapidly evolving needs of a diverse array of customers in life science, pharmaceutical, biotechnology, clinical and molecular diagnostics research, as well as in materials and chemical analysis in various industries and government applications.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.